Lama Binobaid

Dr. Lama Binobaid

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
SASulaiman S Alhudaithi
Sulaiman S Alhudaithi
MKMohd Abul Kalam
Mohd Abul Kalam
LBLama Binobaid
Lama Binobaid
RARAISUDDIN ALI
RAISUDDIN ALI
MAMohammed M. Almutairi
Mohammed M. Almutairi
Abdullah AlshememryAbdullah Alshememry
Abdullah Alshememry
Hepatocellular carcinoma (HCC) exhibits high mortality rates in the advanced stage (>90 %). Sorafenib (SORA) is a targeted therapy approved for the treatment of advanced HCC; however, the reported response rate to such a therapeutic is suboptimal (<3%). Piperine (PIP) is an alkaloid demonstrated to exert a direct tumoricidal activity in HCC and improve the pharmacokinetic profiles of anticancer drugs including SORA. In this study, we developed a strategy to improve efficacy outcomes in HCC using PIP as an add-on treatment to support the first-line therapy SORA using biodegradable Poly (D, L-Lactide-co-glycolide, PLGA) nanoparticles (NPs). SORA and PIP (both exhibit low aqueous solubility) were co-loaded into PLGA NPs (PNPs) and stabilized with various concentrations of polyvinyl alcohol (PVA). The SORA and PIP-loaded PNPs (SP-PNPs) were characterized using Fourier Transform Infrared (FTIR) Spectroscopy, X-ray Powder Diffraction (XRD), Dynamic Light Scattering (DLS), and Scanning Electron Microscopy (SEM), Release of these drugs from SP-PNPs was investigated in vitro at both physiological and acidic pH, and kinetic models were employed to assess the mechanism of drug release. The in vitro efficacy of SP-PNPs against HCC cells (HepG2) was also evaluated. FTIR and XRD analyses revealed that the drugs encapsulated in PNPs were in an amorphous state, with no observed chemical interactions among the drugs or excipients. Assessment of drug release in vitro at pH 5 and 7.4 showed that SORA and PIP loaded in PNPs with 0.5 % PVA were released in a sustained manner, unlike pure drugs, which exhibited relatively fast release. SP-PNPs with 0.5 % PVA were spherical, had an average size of 224 nm, and had a high encapsulation efficiency (SORA ∼ 82 %, PIP ∼ 79 %), as well as superior cytotoxicity compared to SORA monotherapy in vitro. These results suggest that combining PIP with SORA using PNPs may be an effective strategy for the treatment of HCC and may set the stage for a comprehensive in vivo study to evaluate the efficacy and safety of this novel formulation using a murine HCC model.

12 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
SASani Zarewa Abdullahi
Sani Zarewa Abdullahi
LBLama Binobaid
Lama Binobaid
Adam SulaimanAdam Sulaiman
Adam Sulaiman
HSHomood M. As Sobeai
Homood M. As Sobeai
MAMoureq Alotaibi
Moureq Alotaibi
AIAnvarhusein Isab
Anvarhusein Isab
Four novel phosphanegold(I) complexes of the type [Au(PR3)(DMT)].PF6 (1–4) were synthesized from 3-Thiosemicarbano-butan-2-one oxime ligand (TBO) and precursors [Au(PR3)Cl], (where R = methyl (1), ethyl (2), tert-butyl (3), and phenyl (4)). The resulting complexes were characterized by elemental analyses and melting point as well as various spectroscopic techniques, including FTIR and (1H, 13C, and 31P) NMR spectroscopy. The spectroscopic data confirmed the coordination of TBO ligands to phosphanegold(I) moiety. The solution chemistry of complexes 1–4 indicated their stability in both dimethyl sulfoxide (DMSO) and a mixture of EtOH:H2O (1:1). In vitro cytotoxicity of the complexes was evaluated relative to cisplatin using an MTT assay against three different cancer cell lines: HCT116 (human colon cancer), MDA-MB-231 (human breast cancer), and B16 (murine skin cancer). Complexes 2, 3, and 4 exhibited significant cytotoxic effects against all tested cancer cell lines and showed significantly higher activity than cisplatin. To elucidate the mechanism underlying the cytotoxic effects of the phosphanegold(I) TBO complexes, various assays were employed, including mitochondrial membrane potential, ROS production, and gene expression analyses. The data obtained suggest that complex 2 exerts potent anticancer activity against breast cancer cells (MDA-MB-231) through the induction of oxidative stress, mitochondrial dysfunction, and apoptosis. Gene expression analyses showed an increase in the activity of the proapoptotic gene caspase-3 and a reduction in the activity of the antiapoptotic gene BCL-xL, which supported the findings that apoptosis had occurred.

1 July 2020 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
LBLama Binobaid
Lama Binobaid
MMMichal M. Masternak
Michal M. Masternak
Malignant Peripheral Nerve Sheath Tumor (MPNST) is a soft-tissue neurosarcoma. It can occur sporadically, after radiotherapy or in patients with Neurofibromatosis 1 (NF1). The hereditary disorder, NF1, is a common cancer predisposition syndrome. The main genetic feature is the mutation of the NF1 tumor suppressor gene that is inherited in an autosomal dominant, progressive manner. Mutations of the NF1 gene increase the activity of Ras signaling and cause the development of different types of tumors, including subcutaneous and plexiform neurofibromas. These can have further mutations that mediate the transformation into MPNST. Somatic mutations that have been observed are the loss of cell cycle regulators of the CDKN2A gene, and the inactivation of Polycomb Repressive Complex 2 (PRC2), mainly embryonic ectoderm development (EED) or suppressor of zeste 12 homologue (SUZ12). Other molecular pathways that have been targeted for treatment are dual MAPK-mTOR targeting, p53 protein, and MEK-ERK pathway. To advance the therapies focused on delaying or inhibiting malignant tumor formation in NF1, we need to understand the implications of the molecular and genetic pathway that are involved in the transformation into MPNST. (C) 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

1 March 2024 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
LBLama Binobaid
Lama Binobaid
HSHomood M. As Sobeai
Homood M. As Sobeai
KAKhalid Alhazzani
Khalid Alhazzani
LALama AlAbdi
Lama AlAbdi
MAMeshari M. Alwazae
Meshari M. Alwazae
AAAli Alhoshani
Ali Alhoshani
Background: Although national efforts are underway to document the genomic variability of the Saudi population relative to other populations, such variability remains largely unexplored. Genetic variability is known to impact the fate of cells and increase or decrease the risk of a variety of complex diseases including cancer forms. Therefore, the identification of variants associated with cancer susceptibility in Saudi population may protect individuals from cancer or aid in patient-tailored therapies. The endo-lysosomal ion transport genes responsible for cationic ion homeostasis within the cell. We screened 703 single-nucleotide polymorphisms (SNPs) of the endo-lysosomal ion transporter genes in the Saudi population and identified cancer-associated variants that have been reported in other populations. Methods: Utilizing previously derived local data of Whole-Exome Sequencing (WES), we examined SNPs of TPCN1, TPCN2, P2RX4, TRPM7, TRPV4, TRPV4, and TRPV6 genes. The SNPs were identified for those genes by our in-house database. We predicted the pathogenicity of these variants using in silico tools CADD, Polyphen-2, SIFT, PrimateAI, and FATHMM-XF. Then, we validated our findings by exploring the genetics database (VarSome, dbSNP NCB, OMIM, ClinVar, Ensembl, and GWAS Catalog) to further link cancer risk. Results: The WES database yielded 703 SNPs found in TPCN2, P2RX4, TRPM7, TRPV4, and TRPV6 genes in 1,144 subjects. The number of variants that were found to be common in our population was 150 SNPs. We identified 13 coding-region non-synonymous variants of the endo-lysosomal genes that were most common with a minor allele frequency (MAF) of ≥ 1 %. Twelve of these variants are rs2376558, rs3750965, rs61746574, rs35264875, rs3829241, rs72928978, rs25644, rs8042919, rs17881456, rs4987682, rs4987667, and rs4987657 that were classified as cancer-associated genes. Conclusion: Our study highlighted cancer-associated SNPs in the endo-lysosomal genes among Saudi individuals. The allelic frequencies on polymorphic variants confer susceptibility to complex diseases that are comparable to other populations. There is currently insufficient clinical data supporting the link between these SNPs and cancer risk in the Saudi population. Our data argues for initiating future cohort studies in which individuals with the identified SNPs are monitored and assessed for their likelihood of developing malignancies and therapy outcomes.

20 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FAFuad Al-Ghamdi
Fuad Al-Ghamdi
SASara Abou Al-Saud
Sara Abou Al-Saud
HAHessah AlShammari
Hessah AlShammari
LBLama Binobaid
Lama Binobaid
RARashed Almousa
Rashed Almousa
In this study, we investigated the effects of medication electromagnetic waves (MEMW) derived from the anticancer drug doxorubicin on tumor growth of MDA-MB-231 breast cancer cell line in a mouse model. Building on prior research, we explored how MEMW inhibits cancer cell proliferation without the toxic side effects associated with traditional chemotherapy. Twenty female nude mice were xenografted with MDA-MB-231 cells and divided into five groups: a control group, a group treated with doxorubicin only, a group treated with doxorubicin plus MEMW, a group treated with MEMW only, and a group treated with MEMW and topical application of olive oil previously exposed to MEMW.Tumor growth was monitored for 21 days. Friedman and ANOVA tests were used. Significant reductions in tumor size were observed in all treated groups compared to the control group (p < 0.05). The group treated with doxorubicin and MEMW in combination exhibited the highest reduction (72.3%). While elevated serum AST levels indicated liver toxicity in the groups treated with doxorubicin, the normal AST levels in those treated with MEMW only suggest a safer therapeutic profile. Histopathological evaluation revealed cytotoxic effects and enhanced necrosis in the groups that received combination treatment, while immunohistochemical assays indicated reduction in proliferative activity.Gene expression analysis confirmed that doxorubicin upregulated pro-apoptotic Bcl-2-associated X protein (BAX), while proliferating cell nuclear antigen (PCNA) was downregulated, aligning with histopathological findings., the results present a novel, non-invasive treatment approach based on MEMW, which may revolutionize cancer therapy by minimizing toxicity while effectively targeting tumor growth.

14 October 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
FAFuad AlGhamdi
Fuad AlGhamdi
SASara Abou Al-Saud
Sara Abou Al-Saud
HAHessah F AlShammari
Hessah F AlShammari
LBLama Binobaid
Lama Binobaid
RARashed Almousa
Rashed Almousa
In this study, we investigated the effects of medication electromagnetic waves (MEMW) derived from the anticancer drug doxorubicin on tumor growth of MDA-MB-231 breast cancer cell line in a mouse model. Building on prior research, we explored how MEMW inhibits cancer cell proliferation without the toxic side effects associated with traditional chemotherapy. Twenty female nude mice were xenografted with MDA-MB-231 cells and divided into five groups: a control group, a group treated with doxorubicin only, a group treated with doxorubicin plus MEMW, a group treated with MEMW only, and a group treated with MEMW and topical application of olive oil previously exposed to MEMW. Tumor growth was monitored for 21 days. One-way ANOVA tests were used. Significant reductions in tumor growth rate were observed in all treated groups compared to the control group (p < 0.05). The group treated with doxorubicin and MEMW in combination exhibited the highest reduction (85%). While elevated serum AST levels indicated liver toxicity in the groups treated with doxorubicin, the normal AST levels in those treated with MEMW only suggest an improved therapeutic profile. Histopathological evaluation revealed cytotoxic effects and enhanced necrosis in the groups that received combination treatment, while immunohistochemical assays indicated reduction in proliferative activity. Gene expression analysis confirmed that doxorubicin upregulated pro-apoptotic Bcl-2-associated X protein (BAX), while proliferating cell nuclear antigen (PCNA) was downregulated, aligning with histopathological findings., the results present a novel, non-invasive treatment approach based on MEMW, which may offer a promising alternative for cancer therapy by minimizing toxicity while effectively targeting tumor growth.